VolitionRx Limited (NYSE AMERICAN: VNRX) is a diagnostics company that mainly focuses on utilizing blood tests to screen diseases especially cancers. Its flagship platform Nu.Q represents a powerful step-change in rethinking the approach to cancer. It is a simple solution to the challenging problem of an early cancer diagnosis. In today’s CEO Interview, the Executive VP of Investor Relations of VolitionRx, Scott Powell will give us an update on the company’s progress. What is the science behind Nu.Q platform? What is its commercial strategy in the global market? How can VolitionRx’s products help with canine cancer diagnosis and Covid-19? What milestones can investors expect for the next 12 months? Watch this interview to learn about VolitionRx.
About VolitionRx Limited (NYSE AMERICAN: VNRX)
Volition is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of NucleosomicsTM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.
Volition’s research and development activities are centered in Belgium, with additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.
For more information about Volition, visit Volition’s website (http://www.volitionrx.com)
NAI500’s new CEO Interview series is a program where we invite CEOs and senior executives of exciting public companies to uncover great investment opportunities for every day investors. If you don’t want to miss out on the great opportunities that we bring, subscribe to our YouTube channel and other social media channels below!
Disclaimer: NAI is being compensated for this content. Materials contained in this content are for information purposes only and is not intended to constitute an offering of securities in any jurisdiction. Nothing on this content should be construed as an offer, solicitation or recommendation to buy or sell products or securities.